Sterling Capital Management LLC Lowers Holdings in Novo Nordisk A/S (NYSE:NVO)

Sterling Capital Management LLC lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 31.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,319 shares of the company’s stock after selling 4,718 shares during the period. Sterling Capital Management LLC’s holdings in Novo Nordisk A/S were worth $443,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in NVO. AlphaMark Advisors LLC grew its stake in shares of Novo Nordisk A/S by 1.1% in the 2nd quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock valued at $113,000 after buying an additional 30 shares during the period. Trillium Asset Management LLC grew its stake in shares of Novo Nordisk A/S by 0.4% in the 2nd quarter. Trillium Asset Management LLC now owns 11,928 shares of the company’s stock valued at $512,000 after buying an additional 48 shares during the period. Baldwin Investment Management LLC grew its stake in shares of Novo Nordisk A/S by 1.4% in the 2nd quarter. Baldwin Investment Management LLC now owns 8,004 shares of the company’s stock valued at $343,000 after buying an additional 111 shares during the period. Garrison Financial Corp grew its stake in shares of Novo Nordisk A/S by 1.3% in the 2nd quarter. Garrison Financial Corp now owns 11,675 shares of the company’s stock valued at $501,000 after buying an additional 145 shares during the period. Finally, Proficio Capital Partners LLC grew its stake in shares of Novo Nordisk A/S by 6.1% in the 2nd quarter. Proficio Capital Partners LLC now owns 2,622 shares of the company’s stock valued at $111,000 after buying an additional 150 shares during the period. 6.04% of the stock is owned by institutional investors.



Shares of Novo Nordisk A/S (NYSE NVO) traded up $0.78 on Friday, hitting $49.91. 1,238,200 shares of the stock were exchanged, compared to its average volume of 2,164,315. Novo Nordisk A/S has a fifty-two week low of $30.89 and a fifty-two week high of $50.95. The firm has a market cap of $125,281.50, a price-to-earnings ratio of 21.45, a price-to-earnings-growth ratio of 2.93 and a beta of 0.63.

WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/11/11/sterling-capital-management-llc-has-443000-position-in-novo-nordisk-as-nvo.html.

NVO has been the topic of several recent analyst reports. Zacks Investment Research lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, July 17th. BidaskClub upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. BNP Paribas lowered shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a report on Monday, September 25th. Finally, Bank of America Corporation upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, September 6th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $55.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply